NUDT15 and TPMT Pharmacogenomic Testing for Azathioprine‐Induced Adverse Reactions in Immune‐Mediated Skin Diseases
Open Access
- 1 January 2026
- journal article
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 1890124
Abstract
Background: While thiopurine S‐methyltransferase (TPMT) variants are known to correlate with azathioprine (AZA)‐induced adverse effects (AEs), nucleoside diphosphate‐linked moiety X Motif 15 (NUDT15) variants were reported to be more prevalent and correlated with AZA toxicity in Asians. However, the information of association between these genetic variants in immune‐mediated skin diseases (IMSDs) is limited. Objective: To evaluate the prevalence of NUDT15 and TMPT genetic variants and their association with AZA‐induced AEs in patients with IMSDs. Materials and Methods: Patients with IMSDs (e.g., autoimmune bullous diseases and vitiligo) who received AZA for ≥ 4 weeks were included. Data on clinical features, laboratory findings including NUDT15 and TPMT testing, AZA treatment regimens, and AZA‐associated AEs were reviewed and analyzed. Results: Among 103 patients, 18 developed AEs: 13 with myelotoxicity alone, 4 with hepatotoxicity alone, and one with both. The prevalence of NUDT15 and TPMT variants was 16.5% and 2.9%, respectively. In multivariate analysis, both NUDT15 and TPMT variants were significantly associated with AZA‐induced myelotoxicity (OR = 13.56, 95%CI = 2.43–75.64, and p = 0.003 and OR = 42.65, 95%CI = 1.40–1300.13, and p = 0.031, respectively). However, none were significantly related to hepatotoxicity. For AZA‐induced myelotoxicity screening, isolated NUDT15 and TPMT tests are low in sensitivity (LR+ = 4.45, 95%CI = 2.03–9.75, sensitivity 50.0%, and specificity 88.8% and LR+ = 12.70, 95%CI = 1.23–131.00, sensitivity 14.3%, and specificity 98.9%, respectively). While the combination of both tests increases screening ability (LR+ = 5.72, 95%CI = 2.83–11.50, sensitivity 64.3%, and specificity 88.8%). Conclusion: NUDT15 is more common than TPMT variants in Thais. In addition to TPMT, NUDT15 testing should be performed before the initiation of AZA to prevent AZA‐induced myelotoxicity in patients with IMSDs.Keywords
Funding Information
- Mahidol University (RF_67086)
This publication has 23 references indexed in Scilit:
- Landscape of TPMT and NUDT15 Pharmacogenetic Variation in a Cohort of Canadian Pediatric Inflammatory Bowel Disease PatientsInflammatory Bowel Diseases, 2024
- TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics KnowledgebaseThe Journal of Molecular Diagnostics, 2022
- Predictive Value of NUDT15 Variants on Neutropenia Among Han Chinese Patients with Dermatologic Diseases: A Single-Center Observational StudyDermatology and Therapy, 2020
- A Comparison of Azathioprine and Mycophenolate Mofetil as Adjuvant Drugs in Patients with Pemphigus: A Retrospective Cohort StudyDermatology and Therapy, 2019
- Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel DiseaseJAMA, 2019
- Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 UpdateClinical Pharmacology & Therapeutics, 2018
- Susceptibility to 6‐MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemiaBritish Journal of Haematology, 2015
- A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopeniaNature Genetics, 2014
- Off-label Use of Azathioprine in DermatologyArchives of Dermatology, 2011
- Azathioprine in dermatology: The past, the present, and the futureJournal of the American Academy of Dermatology, 2006